Call Our HELPLINE: 1-800-4PD-INFO (473-4636)

FDA Approves Extended-Release Amantadine (GOCOVRI™) for Treatment of Dyskinesia

Statement from the Parkinson's Foundation Medical Director, Michael Okun, MD

"Today, Adamas announces FDA approval of an extended release amantadine capsule called GOCOVRI. This drug will provide a practical once a day solution for dyskinesia management and reducing "off" time. Patients who are currently well managed using multiple doses per day of generic amantadine for dyskinesia will not likely derive additional symptomatic benefits from switching to once a day dosing; however, patients experiencing side effects from amantadine may wish to discuss options with their neurologist.

Both GOCOVRI and generic amantadine use is linked to a risk of side effects such as dizziness, hallucinations or blotching on the skin of the legs.  If you are considering starting this medicine or switching to this medicine we recommend consulting with your doctor.

In an independent Parkinson's Foundation study prior to this approval, we found that generic amantadine use improved dyskinesia in patients.  However, amantadine use does have a risk of side effects including insomnia and hallucinations. GOCORVI has been designed to limit the risk of these complications and it will not carry generic amantadine's warning for insomnia."

Call our Helpline, 1-800-4PD-INFO, or visit www.GOCOVRI.com for more information.

About the Parkinson's Foundation

The Parkinson's Foundation is working toward a world without Parkinson's disease. Formed by the merger of National Parkinson Foundation (NPF) and the Parkinson's Disease Foundation (PDF), the mission of the Parkinson's Foundation is to invest in promising scientific research that will end Parkinson's disease and improve the lives of people with Parkinson's, and their families, through improved treatments, support and the best care. For more information, visit www.parkinson.org, or call (800) 4PD-INFO (473-4636).

About Parkinson's Disease (PD)

Affecting an estimated one million Americans and 10 million worldwide, PD is the second-most common neurodegenerative disease after Alzheimer's and is the 14th-leading cause of death in the United States. It is associated with a progressive loss of motor control (e.g., shaking or tremor at rest and lack of facial expression) as well as non-motor symptoms (e.g., depression and anxiety). There is no cure for PD and 60,000 new cases are diagnosed each year in the United States alone.

# # #

Friday, August 25, 2017
Bal du Printemps Honors Supporters, Raises $460,000 for Research
Thursday, May 21, 2015

One hundred and seventy-five guests attended the annual Bal du Printemps Galapresented by the Parkinson’s Disease Foundation (PDF) at The Metropolitan Club in New York City on Tuesday, May 19, 2015 for an intimate and important evening.Willie Geist, co-anchor of NBC News’ “Today” and co-host of MSNBC’s “Morning Joe,” served as the Master of Ceremonies for the evening.

Parkinson’s Disease Foundation Announces New Members of People with Parkinson’s Advisory Council
Tuesday, May 12, 2015

The Parkinson’s Disease Foundation® (PDF®) is pleased to announce new members of its People with Parkinson’s Advisory Council. The council is made up of people living with Parkinson’s disease and care partners who help drive PDF’s goals of ending the disease and supporting those affected by it.

The National Parkinson Foundation Welcomes Two New Board Members
Monday, April 6, 2015

MIAMI,FL — The National Parkinson Foundation (NPF) announced the election of two new members to its Board of Directors: Gregory E. Katz and Jonathan Levin.

Rasheda Ali Joins Moving Day® Tampa
Monday, March 16, 2015

Rasheda Ali Joins Tampa Bay Residents to Get "Moving" for Parkinson's Disease

The National Parkinson Foundation Invests in the Future of Parkinson's Research
Monday, March 2, 2015

Support Provided for the Next Generation of Movement Disorder Neurologists

The National Parkinson Foundation Welcomes New Board Member
Wednesday, February 18, 2015

MIAMI, FL — The National Parkinson Foundation (NPF) announced the election of Ricardo Caporal to its Board of Directors. 

National Parkinson Foundation Expands Expert Care Network
Wednesday, February 11, 2015

UC San Diego Health System Designated Center of Excellence 

Erin Borger and Paul Blom Join NPF's Board of Directors
Tuesday, January 13, 2015

MIAMI,FL — The National Parkinson Foundation (NPF) announced the election of two new members to its Board of Directors: Erin R. Borger and Paul R. Blom. 

FDA Approves Revolutionary Parkinson's Treatment and NPF Is Helping Deliver it to You
Monday, January 12, 2015

The National Parkinson Foundation (NPF) is pleased to share that the U.S. Food and Drug Administration (FDA) has approved DUOPA™, developed by AbbVie Inc., as a treatment for people with advanced Parkinson's disease.

Pages

mail icon

Subscribe to get the latest news on treatments, research and other updates.